Congenital Heart Disease Clinical Trial
— PBUFOfficial title:
Pre Bypass Ultrafiltration (PBUF) Improves Intraoperative Glucose, Sodium, Potassium and Lactate Levels in Children Requiring Cardiopulmonary Bypass
Verified date | February 2022 |
Source | Boston Children's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Newborn babies and children with congenital heart defects who need heart surgery need to be placed on the heart-lung machine for heart surgery. In order to use the heart-lung machine, the investigators have to use blood and other fluids to fill the tubing. During the operation, ultrafiltration is carried out as standard of care to remove extra fluid. Modified ultrafiltration is also performed after surgery. In this study, the investigators are looking to use the filter additionally before surgery. Using the pre bypass filtration before the subject is placed on the heart-lung machine will allow the investigators to better normalize electrolytes in the blood/fluid mixture used in the heart lung machine. This technique is called pre-bypass ultrafiltration, or PBUF (pronounced "P" Buff). The investigators are conducting a study to see if using PBUF to better normalize electrolytes in the blood will make a difference. The investigators have been adding fluids to prime the heart-lung machine in two different ways. The investigators believe both methods are safe and acceptable but hypothesize that there may be subtle differences in electrolytes and fluid status when one technique is used as opposed to the other. The investigators believe that neither technique introduces risk since both are currently used in practice. The standard method adds blood to the heart-lung machine. The alternate method adds blood to the heart-lung machine and then additional fluid is added and removed to more normalize the electrolytes. The investigators plan to randomized subjects undergoing heart surgery to receive the standard priming method versus PBUF to determine if there is any difference in outcomes. Laboratory and clinical data collected as part of clinical care will be used to determine difference sin outcomes. There will be no additional blood taken for this study. There are no known risks to PBUF. The benefits include helping investigators determine if PBUF does or does not make a difference to how subjects recover after surgery. The investigators believe that providing more normal blood values will either improve the subjects' outcome or have no benefit. The investigators do not anticipate increased risks. Given COVID -19 restrictions, the study is on hold.
Status | Terminated |
Enrollment | 13 |
Est. completion date | September 13, 2021 |
Est. primary completion date | September 13, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 1 Year |
Eligibility | Inclusion Criteria: - All patients < 8 kilograms and < 1 year (to ensure that all patients receive steroids at initiation of CPB) undergoing an index cardiac operation for that hospitalization (using a single PBUF protocol) Exclusion Criteria: - Patients undergoing repeat cardiac surgery within the same admission - Patients undergoing transplants as their index surgery - Patients undergoing Ventricular assist device implantation as their index surgery |
Country | Name | City | State |
---|---|---|---|
United States | Boston Children's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston Children's Hospital |
United States,
Baz EM, Kanazi GE, Mahfouz RA, Obeid MY. An unusual case of hyperkalaemia-induced cardiac arrest in a paediatric patient during transfusion of a 'fresh' 6-day-old blood unit. Transfus Med. 2002 Dec;12(6):383-6. — View Citation
de Vroege R, Wildevuur WR, Muradin JA, Graves D, van Oeveren W. Washing of stored red blood cells by an autotransfusion device before transfusion. Vox Sang. 2007 Feb;92(2):130-5. — View Citation
Delaney M, Axdorff-Dickey RL, Crockett GI, Falconer AL, Levario MJ, McMullan DM. Risk of extracorporeal life support circuit-related hyperkalemia is reduced by prebypass ultrafiltration. Pediatr Crit Care Med. 2013 Jul;14(6):e263-7. doi: 10.1097/PCC.0b013e31828a70c5. — View Citation
Grist G. Boiling the frog: the dangers of elevated sodium in blood primed pumps for infants. AmSECT Today.2012;Nov/Dec:5.
Hackbarth RM, Eding D, Gianoli Smith C, Koch A, Sanfilippo DJ, Bunchman TE. Zero balance ultrafiltration (Z-BUF) in blood-primed CRRT circuits achieves electrolyte and acid-base homeostasis prior to patient connection. Pediatr Nephrol. 2005 Sep;20(9):1328-33. Epub 2005 Jun 10. — View Citation
Hall TL, Barnes A, Miller JR, Bethencourt DM, Nestor L. Neonatal mortality following transfusion of red cells with high plasma potassium levels. Transfusion. 1993 Jul;33(7):606-9. — View Citation
Jeffers A, Gladwin MT, Kim-Shapiro DB. Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radic Biol Med. 2006 Nov 15;41(10):1557-65. Epub 2006 Aug 25. — View Citation
Masalunga C, Cruz M, Porter B, Roseff S, Chui B, Mainali E. Increased hemolysis from saline pre-washing RBCs or centrifugal pumps in neonatal ECMO. J Perinatol. 2007 Jun;27(6):380-4. Epub 2007 Apr 19. — View Citation
Matte GS. Perfusion for Congenital Heart Surgery: Notes on Cardiopulmonary Bypass for a Complex Patient Population. Oxford: Wiley-Blackwell; 2015. Chapter 2, Page 27-32.
Messent M, Sinclair DG, Quinlan GJ, Mumby SE, Gutteridge JM, Evans TW. Pulmonary vascular permeability after cardiopulmonary bypass and its relationship to oxidative stress. Crit Care Med. 1997 Mar;25(3):425-9. — View Citation
Moore GL, Peck CC, Sohmer PR, Zuck TF. Some properties of blood stored in anticoagulant CPDA-1 solution. A brief summary. Transfusion. 1981 Mar-Apr;21(2):135-7. — View Citation
Mumby S, Chaturvedi RR, Brierley J, Lincoln C, Petros A, Redington AN, Gutteridge JM. Iron overload in paediatrics undergoing cardiopulmonary bypass. Biochim Biophys Acta. 2000 Mar 17;1500(3):342-8. — View Citation
Nagashima M, Imai Y, Seo K, Terada M, Aoki M, Shinóka T, Koide M. Effect of hemofiltrated whole blood pump priming on hemodynamics and respiratory function after the arterial switch operation in neonates. Ann Thorac Surg. 2000 Dec;70(6):1901-6. — View Citation
O'Leary MF, Szklarski P, Klein TM, Young PP. Hemolysis of red blood cells after cell washing with different automated technologies: clinical implications in a neonatal cardiac surgery population. Transfusion. 2011 May;51(5):955-60. doi: 10.1111/j.1537-2995.2010.02935.x. Epub 2010 Nov 23. — View Citation
Rao R, Georgieff MK. Iron in fetal and neonatal nutrition. Semin Fetal Neonatal Med. 2007 Feb;12(1):54-63. Epub 2006 Dec 6. Review. — View Citation
Vercaemst L. Hemolysis in cardiac surgery patients undergoing cardiopulmonary bypass: a review in search of a treatment algorithm. J Extra Corpor Technol. 2008 Dec;40(4):257-67. Review. — View Citation
* Note: There are 16 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Glucose in milligrams per deciliter (mg/dL). Normal range 61 to 199 mg/dL | Differences in glucose (mg/dl) at the following time points, and also differences in the percentage of values within the normal range for each time point, for PBUF versus standard care.
Final prime value (in the PBUF group after completion of PBUF and prior to cardio pulmonary bypass (CPB), in the control group prior to CPB) First measured levels on bypass - typically 10 minutes post initiation of bypass Last value on CPB Last value in OR First arrival to ICU |
12 hours | |
Primary | Sodium in milliequivalents per liter (mEq/L). Normal range 135 to 148 mEq/L | Differences in sodium (mEq/L) at the following time points, and also differences in the percentage of values within the normal range for each time point, for PBUF versus standard care.
Final prime value (in the PBUF group after completion of PBUF and prior to cardio pulmonary bypass (CPB), in the control group prior to CPB) First measured levels on bypass - typically 10 minutes post initiation of bypass Last value on CPB Last value in OR First arrival to ICU |
12 hours | |
Primary | Potassium in milliequivalents per liter (mEq/L). Normal range 3.2 to 4.5 mEg/L | Differences in potassium (mEq/L) at the following time points, and also differences in the percentage of values within the normal range for each time point, for PBUF versus standard care.
Final prime value (in the PBUF group after completion of PBUF and prior to cardio pulmonary bypass (CPB), in the control group prior to CPB) First measured levels on bypass - typically 10 minutes post initiation of bypass Last value on CPB Last value in OR First arrival to ICU |
12 hours | |
Primary | Lactate in milliequivalents per liter (mEq/L). Normal range 0.5 to 2.2 mEq/L | Differences in lactate (mEq/L) at the following time points, and also differences in the percentage of values within the normal range for each time point, for PBUF versus standard care.
Final prime value (in the PBUF group after completion of PBUF and prior to cardio pulmonary bypass (CPB), in the control group prior to CPB) First measured levels on bypass - typically 10 minutes post initiation of bypass Last value on CPB Last value in OR First arrival to ICU |
12 hours | |
Secondary | Osmolality in milli osmoles per kilogram (mOsm/Kg). Normal Range 276- 295 mOsm/kg | Differences in osmolality in mOsm/Kg in final prime, first blood draw after CPB and on arrival to cardiac intensive care unit (CICU) for PBUF versus standard care. | 12 hours | |
Secondary | Plasma free hemoglobin in milligrams per deciliter (mg/dL). Normal < 5 mg/dL. | Differences in plasma free hemoglobin in mg/dL in final prime, first blood draw after CPB and on arrival to cardiac intensive care unit (CICU) for PBUF versus standard care. | 12 hours | |
Secondary | Inotrope use | Differences in vasoactive inotrope score between the PBUF and standard care groups at the following time points:
i. Between cessation of CPB and admission to CICU as measured by vasoactive inotrope score (VIS) ii. In CICU as measure by VIS/ 24 hours for first 72 hours |
72 hours | |
Secondary | Body wall edema as measured daily weights in kilograms (Kg) | Differences in body wall edema as measure by daily weights in Kg between the PBUF and standard care groups. | Through study completion (until hospital discharge), an average of 15 days. | |
Secondary | Body wall edema as measured daily weights in kilograms (Kg) | Differences in body wall edema as measure by daily weights in Kg between the PBUF and standard care groups. | Through study completion (until hospital discharge) , an average of 15 days. | |
Secondary | Initial ventilation duration in days and hours | Differences in ventilation duration, Initial (days, hours) until first extubation between the PBUF and standard care groups. | Through study completion (until hospital discharge), an average of 15 days. | |
Secondary | Reintubation as a proportion subjects needing reintubation in each group Reintubation | Difference in proportion of subjects requiring unplanned reintubation for respiratory failure between the PBUF and standard care groups. | Through study completion (until hospital discharge), an average of 15 days. | |
Secondary | Total ventilation duration (days, hours) | Difference in total ventilation duration (includes all periods on the ventilator including period following unplanned reintubation for respiratory failure between the PBUF and standard care groups. | Through study completion (until hospital discharge), an average of 15 days. | |
Secondary | Postoperative Cardiac intensive care unit (CICU) length of stay (LOS) in days, | Difference in postoperative CICU LOS in days between the PBUF and standard care groups. | Through study completion (until hospital discharge), an average of 15 days. | |
Secondary | Postoperative hospital LOS | Difference in postoperative hospital LOS in days between the PBUF and standard care groups. | Through study completion (until hospital discharge), an average of 15 days. | |
Secondary | Composite of major adverse events (Postoperative extra corporeal membrane oxygenation (ECMO), reoperation for bleeding, reoperation for low cardiac output state, circuit clotting events) and mortality. Yes or No | Difference in proportion subjects who have a composite event between the PBUF and standard care groups. | Through study completion (until hospital discharge), an average of 15 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04992793 -
Paediatric Brain Injury Following Cardiac Interventions
|
||
Recruiting |
NCT05213598 -
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
|
||
Completed |
NCT04136379 -
Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
|
||
Completed |
NCT04814888 -
3D Airway Model for Pediatric Patients
|
||
Recruiting |
NCT04920643 -
High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery
|
N/A | |
Completed |
NCT05934578 -
Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training
|
N/A | |
Recruiting |
NCT06041685 -
Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia
|
N/A | |
Recruiting |
NCT05902013 -
Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation
|
N/A | |
Not yet recruiting |
NCT05687292 -
Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery
|
||
Not yet recruiting |
NCT05524324 -
Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT
|
N/A | |
Completed |
NCT02746029 -
Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
|
||
Completed |
NCT03119090 -
Fontan Imaging Biomarkers (FIB) Study
|
||
Completed |
NCT02537392 -
Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease
|
N/A | |
Recruiting |
NCT02258724 -
Swiss National Registry of Grown up Congenital Heart Disease Patients
|
||
Terminated |
NCT02046135 -
Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery
|
Phase 2 | |
Completed |
NCT01966237 -
Milrinone Pharmacokinetics and Acute Kidney Injury
|
||
Recruiting |
NCT01184404 -
Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery
|
N/A | |
Completed |
NCT01548950 -
Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
|
N/A | |
Completed |
NCT01178710 -
Effect of Simvastatin on Cardiac Function
|
N/A |